{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:04:37Z","timestamp":1790431477443,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"DOI":"10.1007\/s10096-026-05677-0","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:55:48Z","timestamp":1790430948000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness and treatment costs of ceftazidime\u2013avibactam versus colistin\u2013meropenem for ICU-acquired MDR gram-negative infections in liver transplant recipients"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1853-1243","authenticated-orcid":false,"given":"Adem","family":"Kose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0224-8459","authenticated-orcid":false,"given":"Nisa","family":"Candas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1300-3393","authenticated-orcid":false,"given":"Seyma","family":"Yasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2915-4666","authenticated-orcid":false,"given":"Sibel Altunisik","family":"Toplu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3905-1182","authenticated-orcid":false,"given":"Funda","family":"Memisoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0449-0356","authenticated-orcid":false,"given":"Elif Seren","family":"Tanriverdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-4850","authenticated-orcid":false,"given":"Huseyin","family":"Kocaaslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5081-7233","authenticated-orcid":false,"given":"Esin","family":"Gunay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"issue":"6","key":"5677_CR1","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jhep.2024.07.032","volume":"81","author":"European Association for the Study of the Liver","year":"2024","unstructured":"European Association for the Study of the Liver (2024) EASL clinical practice guidelines on liver transplantation. J Hepatol 81(6):1040\u20131086","journal-title":"J Hepatol"},{"issue":"4","key":"5677_CR2","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/ajt.14208","volume":"17","author":"JA Fishman","year":"2017","unstructured":"Fishman JA (2017) Infection in organ transplantation. Am J Transpl 17(4):856\u2013879","journal-title":"Am J Transpl"},{"issue":"7","key":"5677_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10071561","volume":"10","author":"N Shbaklo","year":"2022","unstructured":"Shbaklo N, Tandoi F, Lupia T, Corcione S, Romagnoli R, De Rosa FG (2022) Bacterial and viral infections in liver transplantation: new insights from clinical and surgical perspectives. Biomedicines (Basel) 10(7):1561","journal-title":"Biomedicines (Basel)"},{"issue":"4","key":"5677_CR4","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.ajt.2024.10.020","volume":"25","author":"AE Boutzoukas","year":"2025","unstructured":"Boutzoukas AE, Dai W, Cober E, Abbo LM, Komarow L, Chen L et al (2025) Carbapenem-resistant Enterobacterales in solid organ transplant recipients. Am J Transpl 25(4):848\u2013859","journal-title":"Am J Transpl"},{"issue":"1","key":"5677_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13054-020-2742-9","volume":"24","author":"M Falcone","year":"2020","unstructured":"Falcone M, Bassetti M, Tiseo G, Giordano C, Nencini E, Russo A et al (2020) Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae. Crit Care 24(1):29","journal-title":"Crit Care"},{"issue":"1","key":"5677_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/antibiotics8010024","volume":"8","author":"RL Nation","year":"2019","unstructured":"Nation RL, Rigatto MHP, Falci DR, Zavascki AP (2019) Polymyxin acute kidney injury: dosing and other strategies to reduce toxicity. Antibiot (Basel) 8(1):24","journal-title":"Antibiot (Basel)"},{"issue":"2","key":"5677_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/cid\/cix783","volume":"66","author":"D van Duin","year":"2018","unstructured":"van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F et al (2018) Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis 66(2):163\u2013171","journal-title":"Clin Infect Dis"},{"key":"5677_CR8","doi-asserted-by":"crossref","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA (2024) Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis, ciae403","DOI":"10.1093\/cid\/ciae403"},{"issue":"3","key":"5677_CR9","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3947\/ic.2024.0038","volume":"56","author":"SY Park","year":"2024","unstructured":"Park SY, Baek YJ, Kim JH, Seong H, Kim B, Kim YC et al (2024) Guidelines for antibacterial treatment of carbapenem-resistant Enterobacterales infections. Infect Chemother 56(3):308\u2013328","journal-title":"Infect Chemother"},{"issue":"7","key":"5677_CR10","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.ajt.2023.03.011","volume":"23","author":"E P\u00e9rez-Nadales","year":"2023","unstructured":"P\u00e9rez-Nadales E, Fern\u00e1ndez-Ruiz M, Natera AM, Guti\u00e9rrez-Guti\u00e9rrez B, Mularoni A, Russelli G et al (2023) Efficacy of ceftazidime-avibactam in solid organ transplant recipients with bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae. Am J Transplant 23(7):1022\u20131034","journal-title":"Am J Transplant"},{"issue":"1","key":"5677_CR11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1373\/clinchem.2014.221770","volume":"61","author":"R Patel","year":"2015","unstructured":"Patel R (2015) MALDI-TOF MS for the diagnosis of infectious diseases. Clin Chem 61(1):100\u2013111","journal-title":"Clin Chem"},{"issue":"3","key":"5677_CR12","doi-asserted-by":"publisher","first-page":"e0027621","DOI":"10.1128\/JCM.00276-21","volume":"60","author":"CG Giske","year":"2022","unstructured":"Giske CG, Turnidge J, Cant\u00f3n R, Kahlmeter G, EUCAST Steering Committee (2022) Update from the European Committee on Antimicrobial Susceptibility Testing (EUCAST). J Clin Microbiol 60(3):e0027621","journal-title":"J Clin Microbiol"},{"issue":"1","key":"5677_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"BT Tsuji","year":"2019","unstructured":"Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A et al (2019) International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 39(1):10\u201339","journal-title":"Pharmacotherapy"},{"issue":"3","key":"5677_CR14","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18(3):268\u2013281","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"5677_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107152","volume":"63","author":"J Hu","year":"2024","unstructured":"Hu J, Zha L, Yu YW, Su Q, Fang XL, Ji JR et al (2024) Efficacy of ceftazidime-avibactam in the treatment of carbapenem-resistant Klebsiella pneumoniae infections: focus on solid organ transplantation recipients. Int J Antimicrob Agents 63(5):107152","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"5677_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s15010-023-02108-6","volume":"52","author":"J Chen","year":"2024","unstructured":"Chen J, Hu Q, Zhou P, Deng S (2024) Ceftazidime-avibactam versus polymyxins in treating patients with carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. Infection 52(1):19\u201328","journal-title":"Infection"},{"issue":"1","key":"5677_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2025.107650","volume":"67","author":"AT Aslan","year":"2026","unstructured":"Aslan AT, Tanriverdi ES, Kaya SY, Dalgan G, Salto\u011flu N, Y\u0131lmaz E et al (2026) Comparison of ceftazidime-avibactam with other appropriate antimicrobial therapy for the treatment of OXA-48- or KPC-producing Enterobacterales infections in T\u00fcrkiye: a multi-centre retrospective matched-cohort study. Int J Antimicrob Agents 67(1):107650","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"5677_CR18","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/jac\/dkac049","volume":"77","author":"JJ Cast\u00f3n","year":"2022","unstructured":"Cast\u00f3n JJ, Cano A, P\u00e9rez-Camacho I, Aguado JM, Carratal\u00e0 J, Ramasco F et al (2022) Impact of ceftazidime\/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study). J Antimicrob Chemother 77(5):1452\u20131460","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"5677_CR19","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s40121-024-00999-y","volume":"13","author":"RK Shields","year":"2024","unstructured":"Shields RK, Horcajada JP, Kamat S, Irani PM, Tawadrous M, Welte T (2024) Ceftazidime-avibactam in the treatment of patients with bacteremia or nosocomial pneumonia: a systematic review and meta-analysis. Infect Dis Ther 13(7):1639\u20131664","journal-title":"Infect Dis Ther"},{"issue":"5","key":"5677_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-070491","volume":"13","author":"P Yang","year":"2023","unstructured":"Yang P, Li Y, Wang X, Chen N, Lu X (2023) Efficacy and safety of ceftazidime-avibactam versus polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infection: a systematic review and meta-analysis. BMJ Open 13(5):e070491","journal-title":"BMJ Open"},{"issue":"4","key":"5677_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/14787210.2024.2307912","volume":"22","author":"N Gupta","year":"2024","unstructured":"Gupta N, Boodman C, Prayag P, Manesh A, Kumar TP (2024) Ceftazidime-avibactam and aztreonam combination for carbapenem-resistant Enterobacterales bloodstream infections with presumed metallo-\u03b2-lactamase production: a systematic review and meta-analysis. Expert Rev Anti Infect Ther 22(4):203\u2013209","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"5677_CR22","doi-asserted-by":"publisher","first-page":"2641111","DOI":"10.1080\/20523211.2026.2641111","volume":"19","author":"W Zhang","year":"2026","unstructured":"Zhang W, Chen C, Li D, Zhou Z, Sheng B, Hu Y et al (2026) Effectiveness and safety of ceftazidime\/avibactam versus polymyxin B in liver transplant recipients with carbapenem-resistant organism infections: a real-world cohort study. J Pharm Policy Pract 19(1):2641111","journal-title":"J Pharm Policy Pract"},{"issue":"7","key":"5677_CR23","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s40121-025-01164-9","volume":"14","author":"N Hu","year":"2025","unstructured":"Hu N, Xiao F, Chen Y, Gu Q, Liang P, Xu Y et al (2025) Efficacy, safety, and cost-effectiveness analysis of ceftazidime-avibactam versus polymyxin B in the treatment of carbapenem-resistant Enterobacteriaceae infections: a target trial emulation. Infect Dis Ther 14(7):1419\u20131437","journal-title":"Infect Dis Ther"},{"key":"5677_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1118307","volume":"11","author":"W Kong","year":"2023","unstructured":"Kong W, Yang X, Shu Y, Li S, Song B, Yang K (2023) Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Front Public Health 11:1118307","journal-title":"Front Public Health"},{"issue":"2","key":"5677_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/14737167.2021.1964960","volume":"22","author":"FA Var\u00f3n-Vega","year":"2022","unstructured":"Var\u00f3n-Vega FA, Lemos E, Casta\u00f1o GN, Reyes JM (2022) Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to carbapenem-resistant Klebsiella pneumoniae in Colombia. Expert Rev Pharmacoecon Outcomes Res 22(2):235\u2013240","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"4","key":"5677_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2025.104545","volume":"29","author":"J Matuoka","year":"2025","unstructured":"Matuoka J, Pachito DV, Piastrelli F, Fehlberg LCC, Oliveira Junior HA (2025) Economic evaluation of ceftazidime-avibactam vs. polymyxin B for treatment of hospital-acquired and ventilator-associated bacterial pneumonia. Braz J Infect Dis 29(4):104545","journal-title":"Braz J Infect Dis"},{"issue":"3","key":"5677_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2025.100937","volume":"39","author":"I Rodr\u00edguez-Goncer","year":"2025","unstructured":"Rodr\u00edguez-Goncer I, Ruiz-Arabi E, Herrera S, Sab\u00e9 N, Los-Arcos I, Silva JT et al (2025) Management of multidrug-resistant gram-negative bacilli infections in adult solid organ transplant recipients: GESITRA-IC\/SEIMC, CIBERINFEC, and SET recommendations update. Transplant Rev (Orlando) 39(3):100937","journal-title":"Transplant Rev (Orlando)"},{"key":"5677_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2024.12469","volume":"37","author":"MP Freire","year":"2024","unstructured":"Freire MP, Pouch SM, Manesh A, Giannella M (2024) Burden and management of multi-drug resistant organism infections in solid organ transplant recipients across the world: a narrative review. Transpl Int 37:12469","journal-title":"Transpl Int"},{"issue":"5","key":"5677_CR29","doi-asserted-by":"publisher","first-page":"dlae152","DOI":"10.1093\/jacamr\/dlae152","volume":"6","author":"AJ Liu","year":"2024","unstructured":"Liu AJ, Dennis ASM, Fariha Z, Mangalore RP, Macesic N (2024) Multidrug-resistant organism bloodstream infections in solid organ transplant recipients and impact on mortality: a systematic review. JAC Antimicrob Resist 6(5):dlae152","journal-title":"JAC Antimicrob Resist"},{"issue":"1","key":"5677_CR30","doi-asserted-by":"publisher","DOI":"10.1017\/ash.2023.517","volume":"4","author":"H Tsai","year":"2024","unstructured":"Tsai H, Bartash R, Burack D, Swaminathan N, So M (2024) Bring it on again: antimicrobial stewardship in transplant infectious diseases: updates and new challenges. Antimicrob Steward Healthc Epidemiol 4(1):e3","journal-title":"Antimicrob Steward Healthc Epidemiol"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05677-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-026-05677-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05677-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:55:50Z","timestamp":1790430950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-026-05677-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":30,"alternative-id":["5677"],"URL":"https:\/\/doi.org\/10.1007\/s10096-026-05677-0","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]},"assertion":[{"value":"30 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Malatya Clinical Research Ethics Committee (Approval No. 8816\/2025). The study was conducted in accordance with the Declaration of Helsinki. Because of the retrospective study design and the use of anonymized routinely collected clinical data, the requirement for written informed consent was waived by the Ethics Committee.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Artificial intelligence\u2013based tools were used only to support language refinement, reference cross-checking, and preparation of preliminary manuscript drafts. All scientific content, study design, data analysis, interpretation of the results, and the final version of the manuscript were independently reviewed, verified, and approved by the authors, who accept full responsibility for the accuracy and integrity of the work.","order":3,"name":"Ethics","label":"Use of artificial intelligence","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}